BPA
SONN

Beacon Pointe Advisors’s Sonnet BioTherapeutics SONN Stock Holding History

Beacon Pointe Advisors’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7
Closed -$7K – 1232
2021
Q4 		$7K Hold
7
– – ﹤0.01% 921
2021
Q3 		$11K Buy
+7
New +$15.6K ﹤0.01% 894

Other funds holding SONN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CAM
Campion Asset Management Falls Church, Virginia $147M AUM 20.65% 1-Year Est. Return

Beacon Pointe Advisors's SONN Position: Q1 2022 in Review

Beacon Pointe Advisors sold out of Sonnet BioTherapeutics (SONN) in Q1 2022, closing a stake of 7 shares — an estimated $7K sold.

Beacon Pointe Advisors first reported a position in SONN in Q3 2021 and held it in 2 quarters. The position peaked at $11K in Q3 2021. 22 funds tracked by Wall St. Rank hold SONN as of Q1 2022.

  • Beacon Pointe Advisors reported no remaining Sonnet BioTherapeutics position as of Q1 2022 after selling out during the quarter.
  • Beacon Pointe Advisors sold 7 Sonnet BioTherapeutics shares in Q1 2022, an estimated $7K.
  • Beacon Pointe Advisors first reported a position in Sonnet BioTherapeutics in Q3 2021 and held it in 2 quarters.
  • Beacon Pointe Advisors's Sonnet BioTherapeutics position peaked at $11K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q1 2022.

Based on Beacon Pointe Advisors's 13F filing for Q1 2022, filed 17 May 2022.